Evidence map›Paper›PMID 38285883›Full record

ArticleHepatology communications2024

African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis.

Maryam Yazdanfar, Joseph Zepeda, Richard Dean, Jialin Wu, Cynthia Levy, David Goldberg, Craig Lammert, Stacey Prenner, K Rajender Reddy, Daniel Pratt and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Anti-integrin αvβ6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 15 institutions in 2 countries.

Maryam YazdanfarDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, California, USA.
Joseph ZepedaDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, California, USA.
Richard DeanDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, California, USA.
Jialin WuDivision of Gastroenterology and Hepatology, Schiff Center for Liver Disease, University of Miami, Miami, Florida, USA.
Cynthia LevyDivision of Gastroenterology and Hepatology, Schiff Center for Liver Disease, University of Miami, Miami, Florida, USA.
David GoldbergDivision of Gastroenterology and Hepatology, Schiff Center for Liver Disease, University of Miami, Miami, Florida, USA.
Craig LammertIndiana University, Indianapolis, Indiana, USA.
Stacey PrennerDivision of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
K Rajender ReddyDivision of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Daniel PrattUniversity of Colorado, Denver, Colorado, USA.
Lisa FormanUniversity of Colorado, Denver, Colorado, USA.
David N AssisYale University, Hew Haven, Connecticut, USA.
Ellina LytvyakDivision of Preventive Medicine, University of Alberta, Edmonton, Alberta, Canada.
Aldo J Montano-LozaDivision of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada.
Stuart C GordonHenry Ford Health and Wayne State University School of Medicine, Detroit, Michigan, USA.
Elizabeth J CareyMayo Clinic Arizona, Scottsdale, Arizona, USA.
Joseph AhnOregon Health Sciences University, Portland, Oregon, USA.
Barry SchlanskyKaiser Permanente Northwest, Portland, Oregon, USA.
Joshua KorzenikBrigham & Women's Health, Boston, Massachusetts, USA.ORCID 0000-0001-7692-5710
Raffi KaragozianTufts Medical, Boston, Massachusetts, USA.
Bilal HameedUC San Francisco, San Francisco, California, USA.
Shaun ChandnaUniversity of Utah, Salt Lake City, Utah, USA.
Lei YuUniversity of Washington, Seattle, Washington, USA.
Christopher L BowlusDivision of Gastroenterology and Hepatology, University of California Davis, Sacramento, California, USA.
University of California, Davis · USUniversity of Alberta · CAUniversity of Miami · USUniversity of Colorado Denver · USUniversity of Pennsylvania · USBrigham and Women's Hospital · USIndiana University – Purdue University Indianapolis · USKaiser Permanente · USMayo Clinic in Arizona · USOregon Health & Science University · USTufts Medical Center · USUniversity of California, San Francisco · USUniversity of Utah · USWayne State University · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundThe natural history of primary sclerosing cholangitis (PSC) among African Americans (AA) is not well understood.

methodsTransplant-free survival and hepatic decompensation-free survival were assessed using a retrospective research registry from 16 centers throughout North America. Patients with PSC alive without liver transplantation after 2008 were included. Diagnostic delay was defined from the first abnormal liver test to the first abnormal cholangiogram/liver biopsy. Socioeconomic status was imputed by the Zip code.

resultsAmong 850 patients, 661 (77.8%) were non-Hispanic Whites (NHWs), and 85 (10.0%) were AA. There were no significant differences by race in age at diagnosis, sex, or PSC type. Inflammatory bowel disease was more common in NHWs (75.8% vs. 51.8% p=0.0001). The baseline (median, IQR) Amsterdam-Oxford Model score was lower in NHWs (14.3, 13.4-15.2 vs. 15.1, 14.1-15.7, p=0.002), but Mayo risk score (0.03, -0.8 to 1.1 vs. 0.02, -0.7 to 1.0, p=0.83), Model for End-stage Liver Disease (5.9, 2.8-10.7 vs. 6.4, 2.6-10.4, p=0.95), and cirrhosis (27.4% vs. 27.1%, p=0.95) did not differ. Race was not associated with hepatic decompensation, and after adjusting for clinical variables, neither race nor socioeconomic status was associated with transplant-free survival. Variables independently associated with death/liver transplant (HR, 95% CI) included age at diagnosis (1.04, 1.02-1.06, p<0.0001), total bilirubin (1.06, 1.04-1.08, p<0.0001), and albumin (0.44, 0.33-0.61, p<0.0001). AA race did not affect the performance of prognostic models.

conclusionsAA patients with PSC have a lower rate of inflammatory bowel disease but similar progression to hepatic decompensation and liver transplant/death compared to NHWs.

Indexed as

Cholangitis, SclerosingEnd Stage Liver DiseaseInflammatory Bowel DiseasesBlack or African AmericanDelayed DiagnosisHumansRetrospective StudiesSeverity of Illness Index

Identifiers

PMID38285883
PMCPMC10830082
OpenAlexW4391304250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.